Chemotherapy Induced Neutropenia (CIN) Market is segmented By Treatment (Granulocyte Colony-Stimulating Factors (G-CSFs) (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfil ....
Market Size in USD
CAGR4.9%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 4.9% |
Market Concentration | Medium |
Major Players | Amgen Inc., Sandoz, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Mylan N.V. |
The chemotherapy induced neutropenia (CIN) market is estimated to be valued at USD 14.16 Bn in 2024 and is expected to reach USD 19.78 Bn by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. The growth of this market is primarily driven by the growing prevalence of cancer cases worldwide and increasing adoption of chemotherapy as an effective treatment modality.